Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT07215026
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among a NSCLC patients receiving at least 1L SACT (Systemic anticancer therapy)
- Detailed Description
This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among aNSCLC patients receiving at least 1L SACT in Argentina, Brazil, Mexico, Australia, India, Taiwan, Malaysia, Hong Kong, and Turkey. All patient-level data, including patient demographic and clinical characteristics, treatment history, and clinical outcomes, will be collected retrospectively from existing patient medical records provided by participating physicians, without interference with treatment decisions. Informed consent from individual patients will not be required, as this study describes the analysis of deidentified patient data.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 800
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcomes of interest are real-world overall survival (rwOS) 12 month Definition of rwOS rwOS is defined as the interval between the index date and the date of death due to any cause.
\*Patients who are alive or for whom vital status is unknown at the time of data collection will be censored at the date the patient is last known to be alive.
- Secondary Outcome Measures
Name Time Method